Reasons for Hope After an ALS Diagnosis with Dr. Richard Bedlack

CCALS Cultivating Compassion Education Series: Recorded on May 15, 2022.
Dr. Richard Bedlack is the leader of the international ALSUntangled program which utilizes social networking to investigate alternative and off-label treatment options for patients with ALS, and the leader of the ALS Reversals program which attempts to understand why some people with ALS recover from it, and to make this happen more often. He is also one of the head investigators for the NEALS ALS Consortium and is the current Director and Founder of the Duke ALS Clinic.
He grew up in a small town in central Connecticut. He went to college at William and Mary in Virginia, then back to Connecticut for an MD and Ph.D. in Neuroscience at UConn. Finally, he went to Duke where he completed his Medicine Internship, Neurology Residency, Neuromuscular Fellowship, and Masters in Clinical Research Science.
He is currently a Professor of Neurology at Duke and a practicing Neurologist and has won awards for his teaching and patient care, including best Neurology teacher at Duke, Health Care Hero, Strength Hope and Caring Award, America’s Best Doctor, the American Academy of Neurology Patient Advocate of the Year, and the Rasmussen ALS Patient Advocate of the Year. Dr. Bedlack has received ALS research grants, participated in ALS clinical trials, and published more than 100 ALS articles.
Dr. Bedlack's Email | [e-mail]
Dr. Bedkack's Duke Health Profile | www.dukehealth...
ALSUntangled | www.alsuntangl...
NEALS ALS Consortium | www.neals.org/
Dr. Bedlack Disclosures:
Research support from: ALS Association, Healey, MediciNova, Orion
Consulting support from AB Science, ALSA, Alexion, Amylyx, Apellis, Biogen, Biohaven, Brainstorm, Clene, Corcept, Cytokinetics, GenieUS, Guidepoint, ITF Pharma, Mallinkrodt, Orphazyme, Shinkei, Woolsey Pharma
---
Chapters
00:00 Grounding Meditation
2:20 Dr. Bedlack Introduction
5:50 Dr. Bedlack Welcome & Background
8:38 Progression Variability
19:24 Current Treatments
44:45 Research-Progress
1:22:08 Conclusions
1:23:37 Q & A